Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) have received a consensus recommendation of “Moderate Buy” from the fourteen brokerages that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and thirteen have given a buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $87.43.

A number of equities analysts have recently commented on the stock. Wells Fargo & Company increased their price objective on shares of Ultragenyx Pharmaceutical from $72.00 to $75.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Bank of America lowered their price target on Ultragenyx Pharmaceutical from $83.00 to $76.00 and set a “buy” rating on the stock in a research report on Friday, May 31st. Wedbush increased their price objective on Ultragenyx Pharmaceutical from $43.00 to $46.00 and gave the company a “neutral” rating in a report on Friday, August 2nd. Stifel Nicolaus boosted their target price on shares of Ultragenyx Pharmaceutical from $124.00 to $127.00 and gave the stock a “buy” rating in a report on Friday, May 31st. Finally, Barclays cut their price target on shares of Ultragenyx Pharmaceutical from $83.00 to $81.00 and set an “overweight” rating for the company in a research note on Monday, August 5th.

Insider Activity at Ultragenyx Pharmaceutical

In other news, EVP Karah Herdman Parschauer sold 9,806 shares of Ultragenyx Pharmaceutical stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $45.00, for a total transaction of $441,270.00. Following the completion of the sale, the executive vice president now owns 57,981 shares of the company’s stock, valued at $2,609,145. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, EVP Karah Herdman Parschauer sold 9,806 shares of the firm’s stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $45.00, for a total transaction of $441,270.00. Following the transaction, the executive vice president now directly owns 57,981 shares of the company’s stock, valued at $2,609,145. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Corazon (Corsee) D. Sanders sold 1,737 shares of the business’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $41.10, for a total value of $71,390.70. Following the completion of the sale, the director now owns 7,248 shares of the company’s stock, valued at $297,892.80. The disclosure for this sale can be found here. Insiders sold 52,218 shares of company stock worth $2,662,106 in the last ninety days. 5.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Headlands Technologies LLC acquired a new stake in Ultragenyx Pharmaceutical during the first quarter worth about $28,000. nVerses Capital LLC acquired a new stake in shares of Ultragenyx Pharmaceutical during the 2nd quarter worth approximately $33,000. UMB Bank n.a. increased its stake in Ultragenyx Pharmaceutical by 58.1% in the second quarter. UMB Bank n.a. now owns 958 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 352 shares during the last quarter. GAMMA Investing LLC lifted its stake in Ultragenyx Pharmaceutical by 622.3% during the first quarter. GAMMA Investing LLC now owns 1,004 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 865 shares during the last quarter. Finally, Van ECK Associates Corp boosted its holdings in shares of Ultragenyx Pharmaceutical by 34.0% in the 4th quarter. Van ECK Associates Corp now owns 1,578 shares of the biopharmaceutical company’s stock valued at $75,000 after purchasing an additional 400 shares in the last quarter. Institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Stock Performance

NASDAQ:RARE opened at $56.45 on Friday. The stock has a 50-day simple moving average of $48.57 and a 200 day simple moving average of $45.98. Ultragenyx Pharmaceutical has a 52-week low of $31.52 and a 52-week high of $58.73. The company has a market cap of $5.20 billion, a PE ratio of -7.03 and a beta of 0.56.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.52) earnings per share for the quarter, topping the consensus estimate of ($1.64) by $0.12. The company had revenue of $147.03 million during the quarter, compared to analysts’ expectations of $123.20 million. Ultragenyx Pharmaceutical had a negative net margin of 121.57% and a negative return on equity of 266.02%. The business’s quarterly revenue was up 35.7% on a year-over-year basis. During the same period last year, the business earned ($2.25) EPS. On average, research analysts predict that Ultragenyx Pharmaceutical will post -6.24 earnings per share for the current fiscal year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.